Physician profile
Mark Majoch
NPI 1306811823
$2,506.09
in general payments reported to CMS, 2019-2025
29 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $611 · 2021: $649 · 2022: $327 · 2023: $120 · 2024: $192 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $413.98 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $351.24 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $210.76 | 2019-2024 | |
| Amarin Pharma, INC. | $176.70 | 2020-2022 | |
| Ibsa Pharma INC. | $172.66 | 2020-2023 | Tirosint, Licart |
| Allergan, INC. | $124.34 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $106.83 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $95.74 | 2020-2022 | |
| Horizon Therapeutics Plc | $81.12 | 2019-2022 | |
| Amgen INC. | $78.23 | 2019-2025 | Repatha |
| Eisai INC. | $73.18 | 2019-2020 | |
| Boston Scientific Corporation | $66.03 | 2025 | Wavewriter Alpha Prime 16 |
| Arbor Pharmaceuticals, INC. | $65.30 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $64.11 | 2019-2022 | |
| Genentech USA, INC. | $54.27 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.02 | 2019 | |
| Paratek Pharmaceuticals, INC. | $39.28 | 2020-2021 | |
| Abbott Laboratories | $36.96 | 2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2024 | |
| Mylan Specialty L.P. | $35.92 | 2020 | |
| Novartis Pharmaceuticals Corporation | $32.85 | 2022 | |
| Exact Sciences Corporation | $31.34 | 2024-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $22.22 | 2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $17.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.85 | 2021 | |
| Adlon Therapeutics L.P. | $16.80 | 2021 | |
| Medicure Pharma INC. | $16.54 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.52 | 2024 | Caplyta |
| Aytu Biopharma, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Majoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.